SHENZHEN, CHINA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.
Related Questions
How will the reported revenue and profit growth affect CMS's share price in the short term?
What guidance or outlook does CMS provide for the full‑year 2025 performance and its strategic transformation milestones?
How does CMS's growth and margin expansion compare with its main peers in the Chinese pharmaceutical sector?